Fdanewsdrugdailybulletin

Oct. 19, 2017

Vol. 14 No. 202

View Archived Issues

Sign Up Now

Ninth Circuit Dismisses Class Certification Bid in Cymbalta Suit

According to the complaint, the labels understate the percentage of users the symptoms effect at only 1 or 2 percent, when in fact it is closer to 50 percent. Read More

NICE Deal Will Allow Patients Access to Unproven Cancer Drug

NHS patients will have access to the drug while it’s in review. Read More

EMA Outlines Use of Data Extrapolation in Pediatric Applications

An extrapolation plan can address the knowledge gaps inherent in making predictions for how a drug will perform in a new population. Read More

Judge Rules Actavis Infringed on Orexigen’s Contrave Patents

The judge said the claim that bupropion is an obvious choice for further investigation as a weight loss treatment derives from “impermissible hindsight bias.” Read More

Study Hits at Broken 340B Program, PhRMA Says

A shift to more expensive settings can mean higher costs for Medicare beneficiaries and privately insured patients who pay a portion of the treatment charges. Read More